Series B - Ubix Therapeutics - 2020-05-06 - Crunchbase

Ubix Therapeutics raised $12199288 on 2020-05-06 in Series B. Start Free Trial . Chrome Extension

CouponFollow Extension

$12199288
OFF

Series B - Ubix Therapeutics - 2020-05-06 - Crunchbase

4 weeks from now

Ubix Therapeutics raised $12199288 on 2020-05-06 in Series B. Start Free Trial . Chrome Extension

crunchbase.com

$15.79
OFF

Ubix Therapeutics - CB Insights

4 weeks from now

Oct 8, 2024 · Funding, Valuation & Revenue. 4 Fundings. Ubix Therapeutics has raised $15.79M over 4 rounds.. Ubix Therapeutics's latest funding round was a Incubator/Accelerator for on …

cbinsights.com

$29
OFF

Ubix Therapeutics - PitchBook

4 weeks from now

Ubix Therapeutics has raised $29.9M. Who are Ubix Therapeutics’s investors? BNH Investment , GeneN Investment Partners , Medytox Venture Investment , Mirae Asset Venture Investment , …

pitchbook.com

$45
OFF

What Current Series B Trends Say About The US Startup Scene

4 weeks from now

Mar 10, 2022 · Last year, the average Series B round for a U.S. company clocked in at $45 million—up nearly 50 percent from 2020. And so far in 2022, round size has ticked up even …

crunchbase.com

$100
OFF

These Are The Industries Where Series B Funding Is Growing Fastest

4 weeks from now

Nov 29, 2021 · For financial services subsectors, a total of 14 U.S. companies closed Series B rounds of $100 million or more this year. Top Series B recipients included Recharge ($227 …

crunchbase.com

$11250000
OFF

Series B - Alloy Therapeutics - 2020-06-05 - Crunchbase

4 weeks from now

Jun 5, 2020 · Alloy Therapeutics raised $11250000 on 2020-06-05 in Series B. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. …

crunchbase.com

$100
OFF

Crunchbase Stock Price, Funding, Valuation, Revenue ... - CB Insights

4 weeks from now

Funding, Valuation & Revenue. 7 Fundings. Crunchbase has raised $100M over 7 rounds.. Crunchbase's latest funding round was a Series D for $50M on July 20, 2022.. Crunchbase's …

cbinsights.com

$70
OFF

The Week’s 10 Biggest Funding Rounds: Biotech Goes

4 weeks from now

Apr 28, 2023 · Founded in 2020, the company has raised more than $70 million, per Crunchbase. 9. Antiva Biosciences , $53M, biotech: South San Francisco-based Antiva Biosciences — a …

crunchbase.com

$60
OFF

Nutcracker Therapeutics Announces $60 Million Series B Financing …

4 weeks from now

Emeryville, Calif. – September 23, 2020 Financing led by ARCH Venture Partners Company aims to efficiently develop, manufacture and deliver mRNA medicines to patients worldwide using …

nutcrackerx.com

$3555144
OFF

Series A - Ubix Therapeutics - 2019-02-21 - Crunchbase

4 weeks from now

Feb 21, 2019 · Ubix Therapeutics raised $3555144 on 2019-02-21 in Series A. 더벨뉴스 — Ubic Therapeutics attracts 15 billion Series B investment, and series A investment of 4 billion won …

crunchbase.com

$371
OFF

Getting To Series A Has Gotten Harder - Crunchbase News

4 weeks from now

Mar 23, 2023 · Oddly, even funding to AI categories — one of 2023’s buzziest sectors — was down at Series A. Per Crunchbase data, $371 million in Series A funding went to companies …

crunchbase.com

$70000000
OFF

Series B - Remix Therapeutics - 2022-05-17 - Crunchbase

4 weeks from now

May 17, 2022 · Remix Therapeutics raised $70000000 on 2022-05-17 in Series B. Surveyor Capital Surveyor Capital is an investment firm that focuses on access and opportunity to …

crunchbase.com

FAQs about Series B - Ubix Therapeutics - 2020-05-06 - Crunchbase Coupon?

What happened to Series B investment in 2022?

Per Crunchbase data, Series B investment in the second half of 2022 was down over 60% from the year-ago period. For a sense of how far things have fallen, we chart out Series B deal counts and funding for the past nine quarters below. Why Series B? So why single out Series B for scrutiny? ...

What happened to Series B funding in 2023?

In recent months, Series B funding to U.S. startups has fallen sharply. So far in 2023, investment is on track to come in at the lowest quarterly level in more than three years. Search less. Close more. Grow your revenue with all-in-one prospecting solutions powered by the leader in private-company data. ...

Is Series B funding still a good investment?

When technology and biotech valuations began to tumble last year, U.S. Series B funding held up at first, offering one of the brighter areas in a more bearish investment environment. That’s no longer the case. In recent months, Series B funding to U.S. startups has fallen sharply. ...

Are investors backing fewer Series B deals in 2023?

So far in 2023, Crunchbase data shows investors are backing fewer big rounds. There were just six Series B deals of $100 million or more to date this year, an average of fewer than one per week. In 2022, by comparison, there were 90 such rounds, or almost two per week. Still, we are seeing some mega-sized Series B deals this year. ...

Why do we look at Series B trends?

We periodically look at Series B trends because this stage functions as a sort of proxy for the broader venture funding ecosystem: It’s typically the point in a startup’s lifecycle when it has proven technology or market traction and is on the cusp of major scaling. So far in 2023, Crunchbase data shows investors are backing fewer big rounds. ...

Are US Series B rounds slowing down?

But U.S. Series B round announcements haven’t shown any pronounced slowdown yet. In the two weeks following the attack, which commenced on Feb. 23, U.S. companies announced roughly $1.4 billion in Series B investments, on par with the $1.48 billion announced in the prior two weeks. ...